Zacks Investment Research upgraded shares of Integra Lifesciences (NASDAQ:IART) from a sell rating to a hold rating in a report published on Tuesday morning.
According to Zacks, “Integra LifeSciences has underperformed its industry over the past six months. The company’s reduced 2018 revenue guidance fails to instill confidence in the stock. Significant gross margin contractions caused by escalating costs have been a major headwind for the company in the last reported quarter. A tough competitive landscape adds to the woes. However, solid growth across all business segments has been the key growth catalyst for Integra LifeSciences. The company’s successful progress with its channel expansion strategy and Codman integration buoy optimism. Notably, the company announced plans within Orthopedics and Tissue Technologies segment to expand its sales channel, improve focus and competitiveness and better align the company’s product portfolio with clinical customers. Moreover, the strong investments in research and development is encouraging.”
Several other equities research analysts also recently issued reports on IART. BidaskClub downgraded Integra Lifesciences from a buy rating to a hold rating in a research note on Tuesday, December 4th. JMP Securities reduced their price objective on Integra Lifesciences from $66.00 to $62.00 and set a market outperform rating for the company in a research note on Friday, November 2nd. Oppenheimer reissued a buy rating and issued a $70.00 price objective on shares of Integra Lifesciences in a research note on Wednesday, October 31st. Citigroup reduced their price objective on Integra Lifesciences from $66.00 to $60.00 and set a neutral rating for the company in a research note on Friday, November 2nd. Finally, Cantor Fitzgerald set a $54.00 price objective on Integra Lifesciences and gave the stock a hold rating in a research note on Tuesday, January 8th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and six have issued a buy rating to the company’s stock. The stock presently has an average rating of Hold and an average price target of $62.00.
Institutional investors and hedge funds have recently bought and sold shares of the company. Enlightenment Research LLC purchased a new stake in shares of Integra Lifesciences during the 4th quarter worth about $32,000. Legacy Financial Advisors Inc. purchased a new stake in shares of Integra Lifesciences during the 4th quarter worth about $33,000. NumerixS Investment Technologies Inc raised its stake in shares of Integra Lifesciences by 100.1% during the 4th quarter. NumerixS Investment Technologies Inc now owns 2,801 shares of the life sciences company’s stock worth $124,000 after purchasing an additional 1,401 shares in the last quarter. Ffcm LLC raised its stake in shares of Integra Lifesciences by 1,910.6% during the 4th quarter. Ffcm LLC now owns 2,855 shares of the life sciences company’s stock worth $129,000 after purchasing an additional 2,713 shares in the last quarter. Finally, Koshinski Asset Management Inc. purchased a new stake in shares of Integra Lifesciences during the 3rd quarter worth about $201,000. 87.90% of the stock is owned by institutional investors.
About Integra Lifesciences
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.
Featured Story: Options Trading
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.